Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update

@article{Sriretnakumar2015PharmacogeneticsOC,
  title={Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update},
  author={Venuja Sriretnakumar and Eric Huang and Daniel J. M{\"u}ller},
  journal={Expert Opinion on Drug Metabolism \& Toxicology},
  year={2015},
  volume={11},
  pages={1709 - 1731}
}
Introduction: Clozapine (CLZ) is the most effective treatment for treatment-resistant schizophrenia (SCZ) patients, with potential added benefits of reduction in suicide risk and aggression. However, CLZ is also mainly underused due to its high risk for the potentially lethal side-effect of agranulocytosis as well as weight gain and related metabolic dysregulation. Pharmacogenetics promises to enable the prediction of patient treatment response and risk of adverse effects based on patients… Expand
Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications
TLDR
Overall, several gene variants related to antipsychotic response and adverse effects in the treatment of patients with schizophrenia have been reported, and several commercial pharmacogenomic tests have become available, however, further well-designed investigations and replication studies in large and well-characterized samples are needed to facilitate the application of PGx findings to clinical practice. Expand
Pharmacogenetics in Psychiatry.
TLDR
The first pharmacogenetic studies focused on candidate genes, previously known to be relevant to the pharmacokinetics and pharmacodynamics of psychotropic drugs, which may lead to the personalized prescription of existing medications and potentially to the development of innovative ones, thanks to new insights into the genetics of mental illness. Expand
New findings in pharmacogenetics of schizophrenia
TLDR
The findings to date are promising and provide a better understanding of the development of side effects and response to antipsychotics, however, more comprehensive investigations in large, well characterized samples will bring us closer to clinically actionable findings. Expand
Toward personalized medicine in schizophrenia: Genetics and epigenetics of antipsychotic treatment
TLDR
Although pharmacoepigenetics is still in its infancy, consideration of both genetic and epigenetic factors contributing to antipsychotic response and side effects no doubt will be increasingly important in personalized medicine. Expand
Treatment-resistant schizophrenia: current insights on the pharmacogenomics of antipsychotics
TLDR
Clinical pharmacogenomic testing – to personalize clozapine treatment and identify patients at high risk of treatment failure or of adverse events – has moved closer over the last 20 years, however, to develop such testing that could be used clinically will require larger, multicenter, prospective studies. Expand
Clozapine as a Model for Antipsychotic Development
TLDR
This review discusses the history of clozapine, landmark studies, and its clinical advantages and disadvantages, and highlights some of the advances from pharmacogenetic studies on clozAPine and focuses on studies of clazapine using unbiased approaches such as pharmacogenomics and gene expression profiling. Expand
Clozapine’s critical role in treatment resistant schizophrenia: ensuring both safety and use
TLDR
Clozapine remains the only treatment indicated in TRS, but it is dramatically underutilized and efforts must be implemented that ensure its use in this population while maximizing safety. Expand
Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis
TLDR
Clinicians should be aware of this information before starting CLZ use, when treating patients with refractory psychosis, who are alcohol drinkers and carriers of this genetic variant in order to prevent CLZ‐related adverse reactions, and should be replicated in larger samples. Expand
Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex
TLDR
Sex-related differences in clozapine tolerability are confirmed, with a main effect of sex especially for tachycardia, postural hypotension and constipation, although non-life-threatening. Expand
Gene–gene interaction between DRD4 and COMT modulates clinical response to clozapine in treatment-resistant schizophrenia
TLDR
The results highlight the importance of investigating gene–gene interactions, while studying the pharmacogenetics of clozapine, and the need to understand the role of polymorphisms in genes encoding proteins involved in synaptic neurotransmission in schizophrenia. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 118 REFERENCES
The pharmacogenetics of antipsychotic-induced adverse events
TLDR
Overall, genetic studies have been successful in identifying strong findings, in particular for antipsychotic-induced weight gain and to some extent for tardive dyskinesia, and the next challenge will be to create predictive algorithms that can be used for clinical practice. Expand
Pharmacogenetics in schizophrenia: a review of clozapine studies.
TLDR
Efforts to identify key gene mechanisms that will be useful in predicting clozapine response and side effects have not been fully successful and further studies with new analysis approaches and larger sample sizes are still required. Expand
Pharmacogenetics and outcome with antipsychotic drugs
TLDR
The most promising genetic markers of antipsychotic treatment outcomes are discussed, and current translational research efforts that aim to bring these pharmacogenetic findings to the clinic in the near future are presented. Expand
Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia
TLDR
BDNF appears to have a strong association with antipsychotic treatment resistance, and future studies are needed to replicate this finding and further elucidate the biological pathways underlying the association between BDNF and antipsychotics drug response. Expand
Association between CYP1A2 gene single nucleotide polymorphisms and clinical responses to clozapine in patients with treatment-resistant schizophrenia
TLDR
Routine screening for CYP1A2 gene SNPs prior to start clozapine is currently unwarranted, and future longitudinal genome-wide association studies investigating clinical and pharmacogenetic variables together are suggested. Expand
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.
TLDR
The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response in schizophrenia patients, finding that variation in the DRD(2) gene is associated with clinical response to antipsychotics. Expand
Clozapine: A Clinical Review of Adverse Effects and Management
TLDR
The history, pharmacology, management of side effects, and fetal and neonatal effects of clozapine are covered, which have resulted in the expansion of its use from refractory schizophrenia to schizoaffective disorders, affective disorders, some neurological disorders, aggression, as well as psychosis in patients with dementia and parkinsonism. Expand
Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia
TLDR
It is demonstrated that the results of pharmacogenetic studies in schizophrenia depend heavily on their outcome definitions and that combined clinical and pharmacogenetics models have better predictive values. Expand
Association Study of 27 Annotated Genes for Clozapine Pharmacogenetics: Validation of Preexisting Studies and Identification of a New Candidate Gene, ABCB1, for Treatment Response
TLDR
A new candidate gene, ABCB1, is found for treatment response, which may provide a hypothesis on the relationship between the blood-brain distribution of CLZ and its clinical efficacy, and is validated through an integrative study. Expand
Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain.
TLDR
These data implicate MC4R in extreme SGA-induced weight gain and related metabolic disturbances, and could lead to alternative treatment strategies in this population of patients undergoing first exposure to antipsychotic drugs. Expand
...
1
2
3
4
5
...